 |
 |
 |
 |
 |
 |
 |
 |
Press ReleaseMillenia Hope Generates Second MMH Malarex(TM) SaleNew Contract to Also Generate Further Sales Over 12 MonthsMONTREAL, Aug. 15, 2005 -- Millenia Hope Inc., a Delaware Biopharma corporation (OTC Bulletin Board - MLHP; Berlin - MLF), today announced that it has sold 10,000 treatments of MMH Malarex(TM)/MMH 18(TM) to a private clinic in Mali. This sale is the initial order from a second contract that could also generate sales of 100,000 treatments over the next 12 months.Previously, on August 10, 2005, Millenia Hope announced its initial African sale of 25,000 treatments from a contract totaling 100,000 treatments spread over the following 12 months. Leonard Stella, CEO, stated, "It is very satisfying to know that we are part of the solution to such an insidious and devastating problem, the malaria plague. Millenia pledges its very best effort to help in curing this killer disease. "There are 300-500 million malaria-infected individuals globally; three (3) million die annually, of which 1 million are children under five (5) years of age. An effective malaria cure is urgently needed. In many regions, 70% or more of malaria strains are resistant to existing medications and the World Health Organization (WHO) is no longer funding products like chloroquine to which malaria is resistant. MMH Malarex(TM)/MMH 18(TM) cures malaria in those regions where resistant strains are prevalent. MMH Malarex(TM) has cured nearly 1,000 malaria sufferers in its various trials over the last five (5) years. We are saving lives right now!" About Millenia Hope Millenia hope is in the business of developing innovative treatments and quality medication products that will lead to healthier lives. Our people are committed to research and development to deliver on medical needs globally and to bring hope through healthcare solutions. Safe Harbour Statement Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets. For further information, please contact: Mr. Hugo Valente Tel: (514) 846-5757 or (514) 288-8822 Fax: (514) 935-9758 http://www.milleniahope.com admin@milleniahope.com |
 Subscribe and receive targeted press release announcements. Choose from several categories. Sign up today!  Media Searches Reference Tools Journalism Sites Public Relations PR Bookstore Organizations/Assns. Careers |